Long-term effect of cognitive behavioural therapy and doxycycline treatment for patients with Q fever fatigue syndrome: One-year follow-up of the Qure study.


Journal

Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333

Informations de publication

Date de publication:
01 2019
Historique:
received: 04 09 2018
revised: 09 11 2018
accepted: 10 11 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 3 3 2020
Statut: ppublish

Résumé

Previously, we reported a randomized placebo-controlled trial, the Qure study, showing that cognitive behavioural therapy (CBT), and not doxycycline, was significantly more effective than placebo in reducing fatigue severity in Q fever fatigue syndrome (QFS) patients. This follow-up study evaluates the long-term effect of these treatment regimens, 1 year after completion of the original trial. All patients who completed the Qure study, CBT (n = 50), doxycycline (n = 52), and placebo (n = 52), were included in this follow-up study. Between twelve and fifteen months after end of treatment (EOT), patients filled out web-based questionnaires including the main outcome measure fatigue severity, assessed with the Checklist Individual Strength (CIS), subscale fatigue severity. Fatigue severity in the CBT, but not doxycycline or placebo, group was significantly increased at follow-up compared to EOT (respective means 39.5 [95% CI, 36.2-42.9] and 31.3 [95% CI, 27.5-35.1], mean difference 8.2 [95% CI, 4.9-11.6]; P < .001). Fatigue severity scores of CBT (adjusted mean 39.8 [95% CI, 36.1-43.4]) and doxycycline (adjusted mean 41.0 [95% CI, 37.5-44.6]) groups did not significantly differ from the placebo group (adjusted mean 37.1 [95% CI, 33.6-40.7]; P = .92 and P = .38, respectively). The beneficial effect of CBT on fatigue severity at EOT was not maintained 1 year thereafter. Due to its initial beneficial effect and side effects of long-term doxycycline use, we still recommend CBT as treatment for QFS. We suggest further investigation on tailoring CBT more to QFS, possibly followed by booster sessions.

Sections du résumé

BACKGROUND
Previously, we reported a randomized placebo-controlled trial, the Qure study, showing that cognitive behavioural therapy (CBT), and not doxycycline, was significantly more effective than placebo in reducing fatigue severity in Q fever fatigue syndrome (QFS) patients. This follow-up study evaluates the long-term effect of these treatment regimens, 1 year after completion of the original trial.
METHODS
All patients who completed the Qure study, CBT (n = 50), doxycycline (n = 52), and placebo (n = 52), were included in this follow-up study. Between twelve and fifteen months after end of treatment (EOT), patients filled out web-based questionnaires including the main outcome measure fatigue severity, assessed with the Checklist Individual Strength (CIS), subscale fatigue severity.
RESULTS
Fatigue severity in the CBT, but not doxycycline or placebo, group was significantly increased at follow-up compared to EOT (respective means 39.5 [95% CI, 36.2-42.9] and 31.3 [95% CI, 27.5-35.1], mean difference 8.2 [95% CI, 4.9-11.6]; P < .001). Fatigue severity scores of CBT (adjusted mean 39.8 [95% CI, 36.1-43.4]) and doxycycline (adjusted mean 41.0 [95% CI, 37.5-44.6]) groups did not significantly differ from the placebo group (adjusted mean 37.1 [95% CI, 33.6-40.7]; P = .92 and P = .38, respectively).
CONCLUSION
The beneficial effect of CBT on fatigue severity at EOT was not maintained 1 year thereafter. Due to its initial beneficial effect and side effects of long-term doxycycline use, we still recommend CBT as treatment for QFS. We suggest further investigation on tailoring CBT more to QFS, possibly followed by booster sessions.

Identifiants

pubmed: 30654996
pii: S0022-3999(18)30818-3
doi: 10.1016/j.jpsychores.2018.11.007
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Doxycycline N12000U13O

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-67

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Ruud P H Raijmakers (RPH)

Radboud Expert Center for Q Fever, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Ruud.Raijmakers@radboudumc.nl.

Stephan P Keijmel (SP)

Radboud Expert Center for Q Fever, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Stephan.Keijmel@radboudumc.nl.

Evi M C Breukers (EMC)

Radboud Expert Center for Q Fever, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Evi.Breukers@radboudumc.nl.

Gijs Bleijenberg (G)

Expert Center for Chronic Fatigue, Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands. Electronic address: Gijs.Bleijenberg@radboudumc.nl.

Jos W M van der Meer (JWM)

Radboud Expert Center for Q Fever, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Jos.vanderMeer@radboudumc.nl.

Chantal P Bleeker-Rovers (CP)

Radboud Expert Center for Q Fever, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Chantal.Bleeker-Rovers@radboudumc.nl.

Hans Knoop (H)

Expert Center for Chronic Fatigue, Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands; Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: Hans.knoop@amc.uva.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH